Bryan Johnson Says He ‘Cloned’ Himself as a Newborn to Grow Organs

When tech‑savvy billionaire Bryan Johnson announced on X that he’s “cloned” himself “as a newborn,” the internet collectively did a double‑take. The idea of a baby version of yourself swimming in a petri dish sounds straight out of a Michael Bay flick, yet Johnson insists it’s a serious step toward growing his own organs.

He describes the process as creating a store of pluripotent stem cells—cells that can, in theory, become any cell type in the body. In layperson’s terms, it’s like having a blank‑slate version of you that can be coaxed into heart tissue, lung cells, or even a whole organ, should the technology ever catch up.

Now, before you picture a tiny human wriggling around a lab, let’s clear something up: there’s no living clone running around. What Johnson actually did is reprogram ordinary adult cells (think a skin sample) back into an embryonic‑like state. Scientists call these induced pluripotent stem cells, or iPSCs, and they’ve been a hot topic in regenerative medicine for the past decade.

Johnson’s optimism is palpable. He claims that having his own iPSC “baby” will let him become his own “blood boy,” effectively a personal reservoir for repairing damaged lungs, eyes, or other organs. He even goes as far as saying the technology could give us a pathway to reverse aging itself.

Sounds tempting, right? The problem is that most of the applications he’s touting remain very much in the research phase. While we can coax iPSCs to form miniature heart tissues or retinal cells in a dish, we’re nowhere near reliably growing a full‑size, transplant‑ready organ from a person’s own cells. Some labs have experimented with seeding cells onto animal scaffolds—like pig hearts—but those experiments have stalled at the embryonic stage, and no successful human transplants have been reported.

There’s also the alternative route of xenotransplantation, where genetically engineered pig organs are transplanted directly into humans. So far, those procedures have only been tried on patients who were already brain‑dead, and the organs were rejected within days.

All this means that while Johnson’s vision is undeniably bold—and his personal brand thrives on pushing the boundaries—we should take his longevity promises with a generous pinch of salt. The science is promising, but it’s still very much a work in progress.

We’ll keep an eye on Johnson’s “baby clone” experiment, if only because it’s fascinating to watch someone try to turn a sci‑fi plot into a real‑world project. Until then, the future of organ growth and anti‑aging remains a frontier full of hopeful hype and careful skepticism.